Avedro, Inc.

Part of Glaukos Corporation

UEI
XVMEKBSUMGZ7
CAGE
59N76
Primary NAICS
339112 Surgical and Medical Instrument Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Website
glaukos.com
Founded
1998
Employees
251-1K
Estimated annual revenue
$100M-$250M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Equipment & Supplies
  4. Eyewear
SIC code
59 Miscellaneous Retail
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $30,586
FY2025 $74,587
FY2024 $490,143

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Veterans Affairs $30,586

Contract vehicles

Contract awards

Award Agency Obligated Awarded
Travoprost 75MCG 36C25226N0252 Veterans Integrated Service Network 12 (VHA) $169,105
Idose TR 75 MGC implant 36C24525N0897 Veterans Integrated Service Network 5 (VHA) $10,655
Pros implant 36C25925P0637 Veterans Integrated Service Network 19 (VHA) $21,311
Pros implant 36C25925P0638 Veterans Integrated Service Network 19 (VHA) $21,311
Pros implant 36C25924P1445 Veterans Integrated Service Network 19 (VHA) $21,311

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Avedro, Inc., a subsidiary of Glaukos Corporation, manufactures specialized ophthalmic medical devices and pharmaceutical implants sold to the Department of Veterans Affairs and the Defense Health Agency as a full-and-open federal prime contractor without set-aside participation. The company competes on a firm-fixed-price basis across purchase orders, delivery orders, and blanket purchase agreements and holds no SBA designations.

Avedro operates as a 100% prime contractor (24 awards across the source period, zero sub awards) supplying advanced eye-care implants and ophthalmic pharmaceuticals to federal healthcare systems. The product portfolio centers on IDOSE TRAVOPROST 75MCG implants, IDOSE TR ophthalmic implants, and PROS implants — specialized devices for glaucoma and ocular hypertension treatment. Representative prime work includes a $213,105.60 delivery order from Veterans Integrated Service Network 15 for IDOSE TRAVOPROST 75MCG implants (July 2024), a $95,897.52 delivery order from VISN 12 for IDOSE TR 75 CMG implants (June 2024), and a $21,310.56 purchase order from VISN 19 for PROS implants (April 2025). Performance is based at Avedro's Waltham, Massachusetts facility.

Customer concentration is heavily weighted toward military health services. The Defense Health Agency dominates by combined potential value at $8.2 million across four awards (86% of total potential value), followed by three VA regional networks — VISN 15 ($341 thousand), VISN 12 ($290 thousand), and VISN 19 ($85 thousand) — and the Army Medical Command ($325 thousand). Top-five customers account for 97% of combined potential value. The company serves nine distinct customer agencies in total, reflecting broad federal healthcare system exposure but concentrated dollar value in defense health systems.

Avedro holds two active Federal Supply Schedule vehicles under the Pharmaceuticals and Drugs (FSS-61-IB) schedule: a single-award Blanket Purchase Agreement (BPA) with a $106,552.80 ceiling running through January 31, 2030, and a prior Federal Supply Schedule contract with a $584,000.00 ceiling. Seven task orders have been placed against the Pharmaceuticals and Drugs parent vehicle, generating $638 thousand in combined potential value. This indefinite delivery framework enables streamlined ordering across multiple VA regional networks.

Award activity has been modest and episodic. The company received two awards in 2018, one in 2022, four in 2024, five in 2025, and one in 2026. Combined potential value across all 24 awards is $9.5 million, of which $1.4 million has been obligated (15% execution rate). One award with $169 thousand in potential value faces ultimate completion in the next twenty-four months, indicating limited near-term recompete exposure. The company's category concentration clusters in Surgical and Medical Instrument Manufacturing (NAICS 339112, 14 awards) and Pharmaceutical Preparation Manufacturing (NAICS 325412, 7 awards), with secondary coding under Ophthalmic Goods Manufacturing (NAICS 339115, 1 award), reflecting its parent Glaukos Corporation's core market position in eye-care innovation and Avedro's role as the operating subsidiary delivering ophthalmic medical technologies to the federal healthcare market.

Quick answers

Is Avedro, Inc. registered in SAM.gov?

Avedro, Inc.'s SAM.gov registration expired on June 17, 2026.

Which contract vehicles does Avedro, Inc. hold?

Avedro, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

How much has Avedro, Inc. received in federal contracts?

Federal contracts obligated $74,587 to Avedro, Inc. in fiscal year 2025 and $595,316 in fiscal years 2023 through 2027.

What is Avedro, Inc.'s most recent federal award?

Avedro, Inc.'s most recent federal contract award is Travoprost 75MCG (36C25226N0252), from Veterans Integrated Service Network 12 (VHA), on February 1, 2026.

On GovTribe

See Avedro, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors